CR9181A - Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa - Google Patents
Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previaInfo
- Publication number
- CR9181A CR9181A CR9181A CR9181A CR9181A CR 9181 A CR9181 A CR 9181A CR 9181 A CR9181 A CR 9181A CR 9181 A CR9181 A CR 9181A CR 9181 A CR9181 A CR 9181A
- Authority
- CR
- Costa Rica
- Prior art keywords
- therapy
- failed
- antiangiogenesis
- patients
- self
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud describe la terapia con antagonistas de angiogenesis tales como anticuerpos antiVEGF. En particular, la solicitud describe el uso de tales antagonistas para tratar la enfermedad autoinmune en un paciente en quien ha fallado el tratamiento anterior tal como el tratamiento con DMARDs o inhibidores-TNFx.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63716904P | 2004-12-17 | 2004-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9181A true CR9181A (es) | 2008-07-31 |
Family
ID=36177836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9181A CR9181A (es) | 2004-12-17 | 2007-06-13 | Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa |
Country Status (23)
Country | Link |
---|---|
US (2) | US20060134111A1 (es) |
EP (1) | EP1824885A1 (es) |
JP (1) | JP2008524241A (es) |
KR (1) | KR20070086218A (es) |
CN (1) | CN101120020A (es) |
AR (1) | AR052056A1 (es) |
AU (1) | AU2005316403A1 (es) |
BR (1) | BRPI0518105A (es) |
CA (1) | CA2587932A1 (es) |
CR (1) | CR9181A (es) |
IL (1) | IL183347A0 (es) |
MA (1) | MA29366B1 (es) |
MX (1) | MX2007007165A (es) |
NO (1) | NO20073651L (es) |
NZ (1) | NZ555286A (es) |
PE (1) | PE20061075A1 (es) |
RU (1) | RU2007126970A (es) |
SG (1) | SG158089A1 (es) |
SV (1) | SV2006002342A (es) |
TN (1) | TNSN07191A1 (es) |
TW (1) | TW200634026A (es) |
WO (1) | WO2006066086A1 (es) |
ZA (1) | ZA200704898B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000067796A1 (en) * | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
CA2422076A1 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
EA036531B1 (ru) * | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
ES2347340T3 (es) | 2004-09-13 | 2010-10-28 | Genzyme Corporation | Construcciones multimericas. |
GB0612721D0 (en) * | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
WO2008031835A2 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
AR069501A1 (es) * | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
EP2727996A1 (en) * | 2008-11-06 | 2014-05-07 | The Johns-Hopkins University | Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors |
SI2376535T1 (sl) * | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
PT2368118E (pt) * | 2008-12-23 | 2014-01-13 | Merck Patent Gmbh | Biomarcadores para inibidores com atividade anti-angiogénica |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
CN102933231B (zh) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | Cd20抗体及其用途 |
SI2601214T1 (en) | 2010-08-06 | 2018-03-30 | Genzyme Corporation | VEGF antagonist compositions and their use |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
WO2015153514A1 (en) * | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
ES2622983T3 (es) * | 2015-02-11 | 2017-07-10 | Deutsches Krebsforschungszentrum | Terapia contra el cáncer con un parvovirus combinado con bevacizumab |
CR20200392A (es) | 2018-03-09 | 2020-11-17 | Agenus Inc | Anticuerpos anti-cd73 y métodos de uso de los mismos |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL47062A (en) * | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4665077A (en) * | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
IL85746A (en) * | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
WO2000064946A2 (en) * | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
US20040120950A1 (en) * | 2002-12-20 | 2004-06-24 | Kari Alitalo | Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
-
2005
- 2005-12-16 KR KR1020077013483A patent/KR20070086218A/ko not_active Application Discontinuation
- 2005-12-16 TW TW094144950A patent/TW200634026A/zh unknown
- 2005-12-16 US US11/303,811 patent/US20060134111A1/en not_active Abandoned
- 2005-12-16 NZ NZ555286A patent/NZ555286A/en not_active IP Right Cessation
- 2005-12-16 EP EP05854343A patent/EP1824885A1/en not_active Withdrawn
- 2005-12-16 WO PCT/US2005/045600 patent/WO2006066086A1/en active Application Filing
- 2005-12-16 RU RU2007126970/15A patent/RU2007126970A/ru not_active Application Discontinuation
- 2005-12-16 BR BRPI0518105-4A patent/BRPI0518105A/pt not_active IP Right Cessation
- 2005-12-16 JP JP2007546933A patent/JP2008524241A/ja not_active Withdrawn
- 2005-12-16 AR ARP050105315A patent/AR052056A1/es not_active Application Discontinuation
- 2005-12-16 AU AU2005316403A patent/AU2005316403A1/en not_active Abandoned
- 2005-12-16 MX MX2007007165A patent/MX2007007165A/es not_active Application Discontinuation
- 2005-12-16 CA CA002587932A patent/CA2587932A1/en not_active Abandoned
- 2005-12-16 SV SV2005002342A patent/SV2006002342A/es unknown
- 2005-12-16 CN CNA2005800481049A patent/CN101120020A/zh active Pending
- 2005-12-16 SG SG200907898-1A patent/SG158089A1/en unknown
- 2005-12-16 ZA ZA200704898A patent/ZA200704898B/xx unknown
- 2005-12-16 PE PE2005001499A patent/PE20061075A1/es not_active Application Discontinuation
-
2007
- 2007-05-18 TN TNP2007000191A patent/TNSN07191A1/fr unknown
- 2007-05-21 IL IL183347A patent/IL183347A0/en unknown
- 2007-06-13 CR CR9181A patent/CR9181A/es not_active Application Discontinuation
- 2007-07-12 MA MA30069A patent/MA29366B1/fr unknown
- 2007-07-16 NO NO20073651A patent/NO20073651L/no not_active Application Discontinuation
-
2008
- 2008-02-19 US US12/033,557 patent/US20080214789A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080214789A1 (en) | 2008-09-04 |
US20060134111A1 (en) | 2006-06-22 |
NZ555286A (en) | 2010-04-30 |
WO2006066086A1 (en) | 2006-06-22 |
AR052056A1 (es) | 2007-02-28 |
CN101120020A (zh) | 2008-02-06 |
MA29366B1 (fr) | 2008-04-01 |
AU2005316403A1 (en) | 2006-06-22 |
IL183347A0 (en) | 2007-09-20 |
ZA200704898B (en) | 2009-03-25 |
BRPI0518105A (pt) | 2008-11-04 |
SV2006002342A (es) | 2006-06-01 |
TNSN07191A1 (en) | 2008-11-21 |
JP2008524241A (ja) | 2008-07-10 |
EP1824885A1 (en) | 2007-08-29 |
SG158089A1 (en) | 2010-01-29 |
PE20061075A1 (es) | 2006-11-15 |
KR20070086218A (ko) | 2007-08-27 |
MX2007007165A (es) | 2007-08-14 |
RU2007126970A (ru) | 2009-01-27 |
CA2587932A1 (en) | 2006-06-22 |
TW200634026A (en) | 2006-10-01 |
NO20073651L (no) | 2007-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9181A (es) | Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa | |
AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
AR077896A1 (es) | Terapia de baja frecuencia con acetato de glatiramer. uso. acetato de glatiramer. | |
EA200802204A1 (ru) | Применение ингибиторов dpp iv | |
AR083878A1 (es) | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento | |
NZ603319A (en) | Diabetes therapy | |
AR077573A2 (es) | Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende | |
UA95902C2 (ru) | Способ увеличения времени развития заболевания или выживаемости у раковых пациентов | |
AR062522A1 (es) | Tratamiento de desordenes en cartilagos | |
PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
WO2007136518A3 (en) | Treatment of autoimmune disorders | |
BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
SI1680128T1 (sl) | Mio-inozitol heksafosfat za topično uporabo | |
WO2010093993A3 (en) | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance | |
BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
EA200970345A1 (ru) | Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина | |
CA2904533C (en) | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells | |
AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
AR081925A1 (es) | Uso de ranolazina para el tratamiento de la hipertension pulmonar | |
ECSP077843A (es) | Tratamiento o prevención del prurito | |
DK1732551T3 (da) | Perhexilin til behandling af kronisk hjertesvigt | |
CR8584A (es) | Piperazinas derivadas de urea para el tratamiento de la endometrosis | |
ECSP034632A (es) | Uso de compuestos del 6-dimetilaminometil-1-fenil-ciclohexaco sustituido en la terapia de la incontinencia urinaria | |
ATE495750T1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |